Ipsen Restructures Executive Leadership with Three Key Appointments to Drive Growth in Oncology and Rare Disease
核心洞察
Ipsen appointed Mari Scheiffele as Chief Product Officer to lead all medicines in Oncology (搜索) and Rare Disease (搜索), focusing on product development and pipeline innovation.
Andreas Gerber joined from Johnson & Johnson as Head of International to lead operations across all geographies excluding North America.
Caroline Sitbon was promoted to General Counsel after joining from GSK in 2024, creating a gender-balanced Executive Committee.
Global specialty care biopharmaceutical company Ipsen announced significant changes to its Executive Committee on July 23, 2025, appointing three new leaders to key positions as the company continues its strategic transformation across Oncology (搜索), Rare Disease (搜索), and Neuroscience (搜索) therapeutic areas.
Strategic Leadership Appointments
Mari Scheiffele has been appointed Executive Vice President and Chief Product Officer, transitioning from her previous role leading commercial operations for the International Region over the past four years. In her new position, Scheiffele will oversee all medicines in Oncology (搜索) and Rare Disease (搜索) at Ipsen, with responsibilities including driving product development and pipeline innovation for new medicines, as well as leading global brands and life cycle management. She succeeds Bartek Bednarz, who will now lead the newly created Asia, Pacific & China region.
Andreas Gerber joins Ipsen from Johnson & Johnson, where he most recently served as Worldwide Vice-president and Head of the Oncology (搜索) Franchise. As the new Executive Vice President and Head of International, Gerber will lead Ipsen's operations across all geographies excluding North America. His role will focus on driving growth in Ipsen's three therapeutic areas across the International region, leveraging his extensive business acumen and commercial operations experience.
Caroline Sitbon has been promoted to Executive Vice President and General Counsel, advancing from her role as Senior Vice President, Legal Affairs, which she assumed after joining Ipsen from GSK in 2024. In her expanded role, Sitbon will lead legal and business ethics functions and serve as the Board of Directors' General Secretary. She succeeds François Garnier, who is retiring after a distinguished career at Ipsen.
Leadership Vision and Strategic Impact
"These three appointments bring additional highly qualified global leaders to our executive leadership team and I'm delighted that they represent a combination of internal promotions and new leaders that have joined Ipsen," said David Loew, Chief Executive Officer. Loew emphasized that the appointments create a gender-balanced Executive Committee at Ipsen, reflecting the company's commitment to diverse leadership.
The CEO highlighted the strategic importance of these appointments in supporting Ipsen's ongoing transformation, noting that both Scheiffele and Sitbon have demonstrated strong leadership, business insights, and innovative mindsets during their tenure at the company. Regarding Gerber's appointment, Loew expressed confidence that his leadership capabilities will be instrumental in the company's continuous growth trajectory across international markets.
Executive Perspectives on New Roles
Scheiffele expressed her commitment to the expanded role, stating, "I am honored to step into the role of Chief Product Officer at such an exciting time for our company. I am committed to driving innovation, fostering a culture of excellence, and continuing to work with our teams to deliver impact for our customers and patients."
Gerber emphasized his focus on patient impact, saying, "I am thrilled to join Ipsen to lead the International Region and to work, together, with a world-class team to make a real impact on patients' everyday lives. I am looking forward to driving our innovative medicines across the portfolio to create access and adoption for patients and customers worldwide and to realize the full potential of our transformative therapies."
Sitbon highlighted her commitment to compliance and integrity, adding, "It is an honor to take the General Counsel and General Secretary role and be part of this dynamic and fast-growing organization committed to advancing science for patients and consumers. I am very excited to have the opportunity to lead a highly qualified team that ensures our commitment to remain unwavering in compliance and integrity."
Company Profile and Global Reach
Ipsen operates as a global biopharmaceutical company focused on bringing transformative medicines to patients across three therapeutic areas: Oncology (搜索), Rare Disease (搜索), and Neuroscience (搜索). The company's pipeline is supported by nearly 100 years of development experience and maintains global hubs in the United States, France, and the United Kingdom. With teams in more than 40 countries and partnerships worldwide, Ipsen delivers medicines to patients in more than 80 countries.
All three executive appointments will take effect on September 1, 2025, with the new leaders reporting directly to CEO David Loew as Ipsen continues to execute its strategic growth plans across its core therapeutic areas.